Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review

Chitosan nanocarriers: A promising approach for glioblastoma therapy

Glioblastoma is a rapidly growing form of brain tumour originating from the supportive tissues present in the brain or spinal cord. The conventional therapeutic options include the use of alkylating agents, radiation and surgical procedures, that exhibits numerous limitations. The considerably less survival rate, very high incidence of recurrence and lack of effective therapeutic options has made the disease as the most lethal brain cancer. Being widely investigated, nanocarriers assure efficacy in brain targeting. Nano-based systems also hold the edge of higher encapsulation efficiency, ability to encapsulate anticancer therapeutics and effective blood brain barrier (BBB) penetration ability has been proven as one of the most successful means of delivering therapeutic agents in brain interstitial. The extreme biocompatible and biodegradable features of chitosan (CS) have been advantageous in combination with its easy fabrication and modifiable physicochemical behaviour. CS has been extensively investigated in the synthesis of nano-systems for brain targeting of drugs. The mucoadhesive behaviour of CS, cationic nature, and its ability to conjugate with various ligands helps in effective targeting of glioblastoma. This review specifically focuses on the fabrication of various CS-based nanocarriers for glioblastoma therapy, alongside describing its suitability and reflecting the recent research outcomes in glioblastoma therapy.

Advances in metallic nanostructures-assisted laser desorption/ionization mass spectrometry imaging of biological samples: A review

BACKGROUND

Mass spectrometry imaging (MSI) has emerged as a powerful tool for the spatial visualization of biomolecules, driving advances in diverse fields such as biomedical research, plant metabolomics, and forensic science. Incorporating nanostructures, particularly metallic and metal oxide nanoparticles, has revolutionized laser desorption/ionization (LDI)-MSI by enhancing ionization efficiency, spatial resolution, and sensitivity.

RESULTS

This review focuses on the preparation, application, and performance of various metallic nanostructures (e.g., gold, silver, platinum, and metal oxides) in LDI-MSI, emphasizing both fundamental physicochemical properties and their role in improving sensitivity, spatial resolution, and data reproducibility.

SIGNIFICANCE

We provide a comparative assessment of metallic nanostructures versus other types of nanomaterials (quantum dots, carbon-based materials), highlight key advantages and current limitations, and offer a roadmap for future developments in nanomaterial-assisted MSI, including prospective strategies for stabilizing and functionalizing surfaces, exploring alternative laser wavelengths, and ensuring robust analytical workflows.

Strategies and challenges of cytosolic delivery of proteins

The cytosolic delivery of therapeutic proteins represents a promising strategy for addressing diseases caused by protein dysfunction. Despite significant advances, efficient delivery remains challenging due to barriers such as cell membrane impermeability, endosomal sequestration and protein instability. This review summarises recent progress in protein delivery systems, including physical, chemical and biological approaches, with a particular focus on strategies that enhance endosomal escape and targeting specificity. We further discuss the clinical translatability of these approaches and propose future directions for improving delivery efficiency and safety, ultimately unlocking the therapeutic potential of intracellular proteins.

Crossing the blood-brain barrier: nanoparticle-based strategies for neurodegenerative disease therapy

Neurodegenerative conditions, including Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, and Huntington's disease, represent a critical medical challenge due to their increasing prevalence, severe consequences, and absence of curative treatments. Beyond the need for a deeper understanding of the fundamental mechanisms underlying neurodegeneration, the development of effective treatments is hindered by the blood-brain barrier, which poses a major obstacle to delivering therapeutic agents to the central nervous system. This review provides a comprehensive analysis of the current landscape of nanoparticle-based strategies to overcome the blood-brain barrier and enhance drug delivery for the treatment of neurodegenerative diseases. The nanocarriers reviewed in this work encompass a diverse array of nanoparticles, including polymeric nanoparticles (e.g. micelles and dendrimers), inorganic nanoparticles (e.g. superparamagentic iron oxide nanoparticles, mesoporous silica nanoparticles, gold nanoparticles, selenium and cerium oxide nanoparticles), lipid nanoparticles (e.g. liposomes, solid lipid nanoparticles, nanoemulsions), as well as quantum dots, protein nanoparticles, and hybrid nanocarriers. By examining recent advancements and highlighting future research directions, we aim to shed light on the promising role of nanomedicine in addressing the unmet therapeutic needs of these diseases.

Natural macromolecules polysaccharide-based drug delivery systems targeting tumor necrosis factor alpha receptor for the treatment of cancer: A review

Cancer is one of the most significant abnormalities in medical sciences for which a new and efficient therapeutic intervention is desired. Targeting the tumor necrosis factor-alpha receptor appears to have a critical role in both cancer development and immune modality. In this review, an attempt is made to review the potential and avenues of natural macromolecules that have augmented drug delivery systems for specific targeting of the tumor necrosis factor-alpha receptor in cancer therapy. Biological macromolecules, derived from biocompatible and biodegradable sources such as lipids, polysaccharides of natural origin, such as chitosan, hyaluronic acid, alginate, pectin, dextran, starch, cellulose, agar, carrageenan, guar gum, chondroitin sulfate, pullulan, and konjac glucomannan, have been immensely utilized in drug delivery systems for its negligible toxicity mucoadhesive properties, ability to enhance drug stability, and controlled release capabilities. Various novel drug delivery approaches are discussed in detail, including those using polysaccharides, lipids, chitosan, proteins, polymers, dendrimers, exosomes, hydrogels, albumin nanoparticles, silk nanoparticles, and cyclodextrin nanoparticles, incorporating cutting-edge engineering techniques for encapsulation of chemotherapeutic, immunomodulatory, and gene-silencing drugs for site-specific delivery at a site of a tumor. Such macromolecules can mitigate toxicity and even bypass multidrug resistance through their intrinsic property, ligand functionalization for targetability towards receptors. In the present review, an attempt is made to present an outlook for the role of natural macromolecules is being a breakthrough intervention in interfering with tumor necrosis factor-alpha receptor-dependent processes in cancer and a new direction in developing efficient, non-toxic, and personalized therapies for anti-cancer activities.

10Boron-doped carbon nanoparticles as delivery platforms for boron neutron capture therapy and photothermal therapy

The current clinical application of the boron drug boronophenylalanine (BPA) in BNCT faces various issues owing to its low boron loading (approximately 5%), which limits its therapeutic efficacy. Therefore, the development of boron drugs with higher boron contents is essential. Enhancing the boron content in boron drug materials is the focus of this study. Two-dimensional (2D) boron nitride-doped nano graphene (BNNG) with a high boron content of 24.97% ± 1.14% w/w was synthesized via the chemical vapor deposition (CVD) method. The size of BNNG was controlled through gradient density centrifugation. Subsequently, a strategy was proposed that leveraged a boron-nitrogen co-doping process to enhance the boron content. The resulting BN nanosheets that were grown on graphene oxide (GO) exhibited an onion-like structure. To serve as a multifunctional delivery platform, 10B-enriched BNNG was dispersed in an aqueous solution through π-π interactions with pyrene methanol polyethylene glycol carboxylate (PPEG) to form BNNG@PPEG, thus becoming water-dispersible. The synthesized multifunctional BNNG@PPEG material satisfied the requirements for BNCT, chemotherapy, and PTT with a high photothermal conversion efficiency (η = 40.552%). Under 1 W cm-2 laser irradiation, BNNG@PPEG generated a temperature of 55 °C, and the cell survival rate significantly decreased to 36.2% ± 3.5%. Meanwhile, the thermal property of BNNG-DOX@PPEG facilitated the controlled release of doxorubicin (DOX). Under neutron irradiation, the BNNG@PPEG complex exhibited significant antitumor activity, and the cell survival rate significantly decreased to 34.82% ± 6.1%.

Eco-friendly nanotherapeutics: Metallic nanoparticles for targeting breast cancer

Breast cancer continues to be a major cause of death among women globally, with triple-negative breast cancer (TNBC) presenting a particularly difficult challenge due to its aggressive behaviour and the lack of effective treatment options. Nanotechnology, particularly the use of silver nanoparticles (AgNPs), has emerged as a promising avenue in oncological research. This review explores into the escalating field of green synthesis of nanoparticles, emphasizing sustainable approaches utilizing plant-based resources. Critical factors influencing nanoparticle synthesis, including reaction conditions, precursor types, and plant phytochemicals, are explored alongside advanced characterization techniques essential for evaluating nanoparticle properties. Special focus is given to the phytofabrication of silver nanoparticles and their multifaceted roles in breast cancer treatment, with detailed insights into their mechanisms, such as inducing apoptosis, generating reactive oxygen species (ROS), and disrupting mitochondrial function, particularly in TNBC cells. The review further highlights the advantages of plant-derived AgNPs, such as biocompatibility and reduced toxicity, while addressing challenges like scalability, reproducibility, and regulatory hurdles. Concluding with future prospects, this paper reflects the potential of green-synthesized AgNPs as a keystone in next-generation cancer therapeutics, paving the way for innovative and eco-friendly approaches in oncology.

Golden insights for exploring cancer: delivery, from genes to the human body using bimetallic Au/Ag nanostructures

Sweeping contact with cancer continues to rise globally, which has led to advanced research on new treatment approaches; nanotechnology has become crucial to targeted cancer therapy. Within the intimate of nanomaterials, Au/Ag nanostructures have emerged as highly attractive because of their distinctive desirable characteristics and their prospective roles in diagnosis as well as cancer therapy. The nanostructures developed revealed remarkable biocompatibility, optically recursive alteration, and magnificently improved therapeutic effects of gold and silver in conjunction with each other. This review addresses the molecular and systemic aspects of Au/Ag nanostructures in cancer research, including the impact of nanostructures on the molecular genetic pathways and their use of systemic administration in the human organism. We explain some of the related mechanisms of action, such as photothermal therapy (PTT), and photodynamic therapy (PDT), as well as the drug delivery systems where they display potential benefits towards offering a more targeted treatment approach with fewer side effects. The latest development has shown that they have the prospect of real-time imaging and biomarker identification, and owing to this they are being viewed as a tool for individualized treatment. However, there are still some limitations: challenges of scaling up, biological safety, and bringing it to the clinic. It is therefore incumbent upon these managements to overcome these hurdles to optimize for their impact. As a result, the current findings are briefly reviewed, and the development directions are discussed to support the revolutionary role of Au/Ag nanostructures in cancer research and therapy.

Zinc Oxide Nanoparticles in Modern Science and Technology: Multifunctional Roles in Healthcare, Environmental Remediation, and Industry

Zinc oxide nanoparticles (ZnO NPs) have garnered significant attention across various scientific and technological domains due to their unique physicochemical properties, including high surface area, photostability, biocompatibility, and potent antimicrobial activity. These attributes make ZnO NPs highly versatile, enabling their application in biomedicine, environmental science, industry, and agriculture. They serve as effective antimicrobial agents in medical treatments and as catalysts in environmental purification processes, owing to their ability to generate reactive oxygen species (ROS) and exhibit photocatalytic activity under UV light. Moreover, ZnO NPs are being increasingly employed in advanced drug delivery systems and cancer therapies, highlighting their potential in modern medicine. Their growing popularity is further supported by their ease of synthesis, cost-effectiveness, and capacity for diverse functionalization, which expand their utility across multiple sectors. This review focuses on research from the past five years (2020-2025) on the practical uses of ZnO nanoparticles in the biomedical, environmental, industrial, and agricultural fields. It also highlights current trends, existing challenges, and future perspectives. By examining these aspects, the article provides a comprehensive understanding of the versatile roles of ZnO NPs and their emerging significance in science and technology.

Biological activities of citrus fruit-derived copper oxide nanoparticles: towards sustainable antimicrobial and antioxidant solutions

The synthesis of CuO NPs from Citrus fruit peel waste is a noteworthy strategy for the effective repurposing utilization of waste and its application in therapeutic studies. Synthesized copper oxide nanoparticles (CuO NPs) from citrus fruit extracts displayed a dark greenish-black colour with sizes ranging from 379.41, 113.19 and 142.76 nm of lemon, orange and tangerine CuO NPs. Phytochemical screening confirmed the presence of phytochemicals in the extracts wherein lemon CuO NPs lacked flavonoids and cardiac glycosides, while orange CuO NPs lacked alkaloids and flavonoids, and tangerine CuO NPs lacked only alkaloids. The decrease in phenolic concentration in CuO NPs was attributed to complex formation with metal ions. Tangerine CuO NPs exhibited the highest antioxidant activity, while lemon CuO NPs showed the highest total antioxidant capacity. Antibacterial activity increased with CuO NP concentration, with tangerine CuO NPs displaying the highest activity against both Bacillus subtilis subtilis strain 168 and Escherichia coli strain PU-1 isolated from Ghagghar river, Haryana, India. This activity was linked to the disruption of bacterial cell membranes and oxidative stress, supported by the interaction between CuO NPs and bacterial cell components. These findings contribute to understanding of various potential applications of citrus fruit-derived CuO NPs in antimicrobial and antioxidant therapies.

Emerging nanotechnologies and their role in early ovarian cancer detection, diagnosis and interventions

Ovarian cancer presents a significant public health challenge, often being diagnosed at advanced stages due to the limitations of current detection methods. This systematic review addresses the urgent need for innovative approaches to enhance early detection and diagnosis of ovarian cancer. We systematically evaluate recent advancements in nanotechnology, focusing specifically on their novel applications and potential in comparison to traditional diagnostic modalities. Our analysis encompasses a wide range of studies investigating nanoparticles, biosensors, advanced imaging techniques, and biomarker detection platforms, with an emphasis on evaluating key performance indicators such as detection rates, turnaround times, and the accuracy of distinguishing cancerous from non-cancerous tissues. Our findings indicate that nanotechnology-based approaches have the potential to significantly improve early detection capabilities for ovarian cancer. Notably, studies on nanoparticle-based imaging techniques and biosensors consistently demonstrate high sensitivity and specificity for identifying ovarian cancer biomarkers, with detection rates exceeding 90% reported for early-stage cancers in several instances. This review underscores the promise of emerging nanotechnologies to transform the landscape of early detection and diagnosis, offering a pathway toward earlier diagnoses, enhanced therapeutic interventions, and improved patient outcomes. We advocate for future research dedicated to the translational efforts required to move these technologies from bench to bedside, ensuring their effectiveness is validated across diverse clinical populations.

Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential

In recent years, magnolol (MG), a natural active compound of polyphenolic nature, has garnered significant interest for its anti-cancer effects. Numerous studies conducted on cell lines and animal models have indicated a positive impact of administering drugs or semi-synthesized products derived from MG, including a decreased incidence of various cancers. This review aims to illustrate the underlying cellular and molecular basis of its actions. The article includes in-depth explanations of phytochemistry, semi-synthetic derivatives, bioavailability, pharmacokinetics, preclinical research, anti-tumor mechanisms, human clinical studies, toxicity, side effects, and safety. It also demonstrates that, in contrast to the wealth of synthetic medications, MG is highly effective against bladder, colon, gastric, skin, liver, lung, gallbladder, and prostate cancers. The findings of this review indicate that MG is a promising candidate as an anti-tumor agent, and future research should focus on developing new semi-synthetic derivative compounds with potential anti-tumor properties.

Recent advances in PD-L1 siRNA nanocarriers for cancer therapy

Tumor immune evasion depends on the programmed death-ligand 1 (PD-L1) mechanism, making it a prominent target in cancer therapy. Small interfering RNA (siRNA) designed to inhibit PD-L1 expression presents an innovative approach for boosting immunity against tumors. However, the therapeutic use of siRNA faces challenges, primarily due to its instability and inefficient cellular delivery. Recent advancements in nanocarrier technologies have shown promise in overcoming these obstacles, improving the delivery and efficacy of PD-L1 siRNA. This review comprehensively explores various nanocarrier systems, including lipid nanoparticles, polymeric carriers, and inorganic nanoparticles, highlighting their design innovations and applications in targeting PD-L1 in diverse cancer models. We discuss the synergistic effects of PD-L1 siRNA delivered via nanocarriers in conjunction with chemotherapy and immunomodulators, showcasing their potential to boost immune responses and reduce tumor growth. Additionally, we address ongoing challenges such as optimizing biodistribution and minimizing off-target effects, which hinder clinical translation. By synthesizing recent research findings, this review aims to illuminate the transformative potential of PD-L1 siRNA nanocarriers in cancer immunotherapy, paving the way for future studies aimed at enhancing therapeutic strategies and improving patient outcomes.

Nanoparticle Albumin-Bound Bortezomib: Enhanced Antitumor Efficacy and Tumor Accumulation in Breast Cancer Therapy

Nanoparticle albumin-bound (NAB) formulations are emerging as a viable strategy for the intravenous delivery of poorly water-soluble drugs. This study aims to improve the therapeutic profile of Bortezomib (BTZ), addressing its low solubility and significant systemic toxicity through the development of NAB-BTZ nanoparticles. The synthesized nanoparticles exhibited an average size of 296.47 ± 10 nm and a high drug encapsulation efficiency of 75%, and a drug loading of 10%. NAB-BTZ displayed a controlled, pH-sensitive release profile, with 59% release at pH 5.4 (mimicking tumor environments) and 46% at pH 7.4 after 12 h. In vitro assays demonstrated that NAB-BTZ significantly reduced the viability of 4T1 mammary carcinoma cells in a dose- and time-dependent manner, increasing late apoptosis from 6% to 54% after 48 h, compared to 24% for free BTZ. At molecular level, NAB-BTZ induced apoptosis by upregulating p53 and Bax, downregulating Bcl-2, and activating caspases 3 and 7. In vivo tests in a murine 4T1 breast cancer model showed that NAB-BTZ substantially inhibited tumor growth, achieving an average tumor volume of 916 mm3 by day 31 versus 1400 mm3 for free BTZ, leading to an improved survival rate of 100% compared to 83% in the BTZ group. Technetium-99m (99mTc) labeling and SPECT imaging confirmed enhanced targeting capability, showing preferential accumulation of NAB-BTZ in tumor sites compared to free BTZ. These findings suggest that NAB-BTZ not only improves antitumor efficacy but also enhances its safety profile, underscoring its clinical potential in breast cancer therapy.

The use of aptamers as therapeutic inhibitors and biosensors of TNF-alpha

Tumor necrosis factor-alpha (TNF-α) is a pivotal cytokine in the pathogenesis of numerous inflammatory and autoimmune diseases. Precise and sensitive detection of TNF-α is essential for both clinical applications and research endeavors. In the realm of cytokine detection, particularly TNF-α, the development of highly sensitive and specific biosensors has become a focal point. The biosensing landscape encompasses a variety of biorecognition elements, each with its unique set of characteristics. TNF inhibitors come with a significant price tag and, notably, do not yield positive responses in all patients. Despite the availability of numerous FDA-approved biologic agents (e.g., infliximab, adalimumab, certolizumab pegol, etc.) and monoclonal antibodies (e.g., adalimumab) targeting TNF-α, aptamers tailored for blocking TNF-α activities have yet to receive approval. Aptamers have rapidly gained recognition as readily available, versatile, and highly effective molecular tools for both therapeutic and diagnostic purposes in the context of TNF-alpha. In this manuscript, we explore the potential of short single-stranded DNA or RNA sequences known as aptamers as biorecognition elements in biosensors designed for the detection of TNF-α. We delve into the progress made in the development of aptamer-based TNF-α inhibitors and shed light on successful studies in this burgeoning field.

Nano-enabled pharmacogenomics: revolutionizing personalized drug therapy

The combination of pharmacogenomics and nanotechnology science of pharmacogenomics into a highly advanced single entity has given birth to personalized medicine known as nano-enabled pharmacogenomics. This review article covers all aspects starting from pharmacogenomics to gene editing tools, how these have evolved or are likely to be evolved for pharmacogenomic application, and how these can be delivered using nanoparticle delivery systems. In this prior work, we explore the evolution of pharmacogenomics over the years, as well as new achievements in the field of genomic sciences, the challenges in drug creation, and application of the strategy of personalized medicine. Particular attention is paid to how nanotechnology helps avoid the problems that accompanied the development of pharmacogenomics earlier, for example, the question of drug resistance and targeted delivery. We also review the latest developments in nano-enabled pharmacogenomics, such as the coupling with other nanobio-technologies, artificial intelligence, and machine learning in pharmacogenomics, and the ethical and regulatory aspects of these developing technologies. The possible uses of nanotechnology in improving the chances of pated and treating drug-resistant cancers are exemplified by case studies together with the current clinical uses of nanotechnology. In the last section, we discuss the future trends and research prospects in this dynamically growing area, stressing the importance of further advancements and collaborations which will advance the nano-enabled pharmacogenomics to their maximum potential.

Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology

BACKGROUND

Cancer treatments often exploit oxidative stress to selectively kill tumour cells by disrupting their lipid peroxidation membranes and inhibiting antioxidant enzymes. However, lipid peroxidation plays a dual role in cancer progression, acting as both a tumour promoter and a suppressor. Balancing oxidative stress through antioxidant therapy remains a challenge, as excessive antioxidant activity may compromise the efficacy of chemotherapy and radiotherapy.

AIM

This review explores the role of antioxidants in mitigating lipid peroxidation in cancer therapy while maintaining treatment efficacy. It highlights recent advancements in nanotechnology-based targeted antioxidant delivery to optimize therapeutic outcomes.

METHODS

A comprehensive literature review was conducted using reputable databases, including PubMed, Scopus, Web of Science, and ScienceDirect. The search focused on publications from the past five years (2020-2025), supplemented by relevant studies from earlier years. Keywords such as "antioxidants," "lipid peroxidation," "nanotechnology in cancer therapy," and "oxidative stress" were utilized. Relevant articles were critically analysed, and graphical illustrations were created.

RESULTS

Emerging evidence suggests that nanoparticles, including liposomes, polymeric nanoparticles, metal-organic frameworks, and others, can effectively encapsulate and control the release of antioxidants in tumour cells while minimizing systemic toxicity. Stimuli-responsive carriers with tumour-specific targeting mechanisms further enhance antioxidant delivery. Studies indicate that these strategies help preserve normal cells, mitigate oxidative stress-related damage, and improve treatment efficacy. However, challenges such as bioavailability, stability, and potential interactions with standard therapies remain.

CONCLUSION

Integrating nanotechnology with antioxidant-based interventions presents a promising approach for optimizing cancer therapy. Future research should focus on refining lipid peroxidation modulation strategies, assessing oxidative stress profiles during treatment, and employing biomarkers to determine optimal antioxidant dosing. A balanced approach to antioxidant use may enhance therapeutic efficacy while minimizing adverse effects.

Colistin-Conjugated Selenium Nanoparticles: A Dual-Action Strategy Against Drug-Resistant Infections and Cancer

Background/Objective: Antimicrobial resistance (AMR) and therapy-resistant cancer cells represent major clinical challenges, necessitating the development of novel therapeutic strategies. This study explores the use of selenium nanoparticles (SeNPs) and colistin-conjugated selenium nanoparticles (Col-SeNPs) as a dual-function nanotherapeutic against multidrug-resistant Pseudomonas aeruginosa, antifungal-drug-resistant Candida spp., and human breast carcinoma (MCF-7) cells. Methods: SeNPs were synthesized and characterized using UV-Vis spectroscopy, atomic force microscopy (AFM), energy-dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD), field emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), and Fourier-transform infrared spectroscopy (FTIR), confirming their nanoscale morphology, purity, and stability. Results: The antimicrobial activity of SeNPs and Col-SeNPs was assessed based on the minimum inhibitory concentration (MIC) and bacterial viability assays. Col-SeNPs exhibited enhanced antibacterial effects against P. aeruginosa, along with significant downregulation of the mexY efflux pump gene, which is associated with colistin resistance. Additionally, Col-SeNPs demonstrated superior antifungal activity against Candida albicans, C. glabrata, and C. krusei compared to SeNPs alone. The anticancer potential of Col-SeNPs was evaluated in MCF-7 cells using the MTT assay, revealing dose-dependent cytotoxicity through apoptosis and oxidative stress pathways. Although MCF-7 is not inherently drug-resistant, this model was used to explore the potential of Col-SeNPs in overcoming resistance mechanisms commonly encountered in cancer therapy. Conclusions: these findings support the promise of Col-SeNPs as a novel approach for addressing both antimicrobial resistance and cancer treatment challenges. Further in vivo studies, including pharmacokinetics and combination therapies, are warranted to advance clinical translation.

Progression of photoresin-based microneedles: From established drug delivery to emerging biosensing technologies

Microneedles have emerged as a highly promising technology for advancing chemical biosensing and drug delivery applications, offering a minimally invasive, efficient, and versatile approach to healthcare innovation. This review provides a comprehensive analysis of photoresin-based microneedles, with a particular focus on SU-8 photoresin due to its favorable mechanical properties, biocompatibility, and ease of fabrication. Advanced techniques for surface modification are discussed to enhance the functionality of microneedles, enabling their application in precise biochemical diagnostics and effective drug therapy. Additionally, a concise overview of the two-photon polymerization technology is presented, emphasizing its remarkable potential in the production of microneedle arrays. By examining the various types of resins employed in the production of microneedles and their integration with nanostructures, this review offers valuable insights into the development and optimization of microneedle-based systems for diverse healthcare purposes.

Transferrin Tethered Fluorescent Organic Nanoparticles for Receptor-Mediated Targeted Delivery of Paclitaxel to Cancer Cells

Cancer remains a critical global issue, marked by its high mortality rates. Despite achieving remarkable progress in cancer treatments, conventional chemotherapeutic drugs face numerous limitations. To this end, nanomaterial-based targeted drug delivery systems have emerged as a hope of promise. In this study, we report the design and development of transferrin (Tf) tethered naphthalene-diimide-based fluorescent organic nanoparticles (NDI-OH-Tf) for targeted delivery of paclitaxel to cancer cells with over expressed transferrin receptors (TfR). Spherical NDI-OH FONPs were fabricated through J-type of aggregation of NDI-OH amphiphiles in a 1:99 (v/v) DMSO-H2O mixture. These NDI-OH FONPs exhibited aggregation induced emission (AIE) at an emission wavelength of λem = 594 nm. The hydroxyl groups on the surface of the NDI-OH FONPs were conjugated with carboxyl groups of transferrin, forming NDI-OH-Tf FONPs. These NDI-OH-Tf FONPs were successfully used for targeted bioimaging and drug delivery to TfR+ cancer cells through ligand receptor interaction between transferrin and TfR. Notably, paclitaxel loaded NDI-OH-Tf exhibited ∼2.9-fold higher efficacy toward TfR+ cancer cells compared to normal cells and ∼3.3-fold higher cytotoxicity than free PTX due to transferrin mediated targeted accumulation of PTX in cancer cells.

Chitosan and hyaluronic acid in breast cancer treatment: Anticancer efficacy and nanoparticle and hydrogel development

The pervasive global health concern of breast cancer necessitates the development of innovative therapeutic interventions to enhance efficacy and mitigate adverse effects. Chitosan and hyaluronic acid, recognized for their biocompatibility and biodegradability, present compelling options for the novel drug delivery systems and therapeutic platforms in the context of breast cancer management. This review will delineate the distinctive attributes of chitosan and hyaluronic acid, encompassing their inherent anticancer properties, targeting capabilities, and suitability for chemical modifications along with nanoparticle development. These characteristics render them exceptionally well-suited for the fabrication of nanoparticles and hydrogels. The intrinsic anticancer potential of chitosan, in conjunction with its mucoadhesive properties, and the robust binding affinity of hyaluronic acid to CD44 receptors, facilitate specific drug delivery to the malignant cells, thus circumventing the limitations inherent in traditional treatment modalities such as chemotherapy. The incorporation of these materials into nanocarriers allows for the co-delivery of therapeutic agents, thereby potentiating synergistic effects, while hydrogel systems provide localized, controlled drug release and facilitate tissue regeneration. An analysis of advancements in their synthesis, functionalization, and application is presented, while also acknowledging challenges pertaining to scalability and clinical translation.

Current Research in Drug-Free Cancer Therapies

Cancer treatment has historically depended on conventional methods like chemotherapy, radiation, and surgery; however, these strategies frequently present considerable limitations, including toxicity, resistance, and negative impacts on healthy tissues. In addressing these challenges, drug-free cancer therapies have developed as viable alternatives, utilizing advanced physical and biological methods to specifically target tumor cells while reducing damage to normal tissues. This review examines several drug-free cancer treatment strategies, such as high-intensity focused energy beams, nanosecond pulsed electric fields, and photothermal therapy as well as the use of inorganic nanoparticles to promote selective apoptosis. We also investigate the significance of targeting the tumor microenvironment, precision medicine, and immunotherapy in the progression of personalized cancer therapies. Although these approaches demonstrate significant promise, challenges including scalability, safety, and regulatory obstacles must be resolved for clinical application. This paper presents an overview of current research in drug-free cancer therapies, emphasizing recent advancements, underlying scientific principles, and the steps required for clinical implementation.

Enhancing Boron Neutron Capture Therapy (BNCT) with Materials Based on COSAN-Functionalized Nanoparticles

Background/Objectives: Boron neutron capture therapy (BNCT) is a promising approach for selectively targeting and destroying malignant cells using 10B isotopes. A significant challenge in BNCT lies in the development of efficient boron delivery systems that ensure adequate boron accumulation within tumor cells. This study aims to synthesize, characterize, and evaluate COSAN-functionalized nanoparticles (NP@I-COSAN) as a potential boron carrier for BNCT. Methods: Hybrid nanoparticles were synthesized by conjugating monoiodinated cobaltabisdicarbollides (I-COSAN) to commercially available acrylic polymer-based nanoparticles. Functionalization and cellular uptake were confirmed through FTIR, TGA, UV-Vis spectroscopy, and TEM/EDX analyses. Biocompatibility was evaluated by assessing cytotoxicity in HeLa cells and C. elegans as an in vivo model. Intracellular boron uptake was quantified using ICP-MS, with results compared to those obtained with 4-borono-L-phenylalanine conjugated to fructose (f-BPA). An in vitro BNCT proof-of-concept assay was also performed to evaluate therapeutic efficacy. Results: NP@I-COSAN demonstrated low cytotoxicity and efficient internalization in cells. ICP-MS analysis revealed stable boron retention, comparable to traditional boron agents. The BNCT assay further showed that NP@I-COSAN was effective in inducing tumor cell apoptosis, even at lower boron concentrations than conventional treatments. Conclusions: These results underscore the potential of NP@I-COSAN as an effective boron delivery system for BNCT, offering a promising strategy to enhance boron accumulation within tumor cells and improve treatment efficacy.

Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine

Recent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents. This review discusses the evolutionary role of nanocarriers, hydrogels, and bioresponsive polymers that offer enhanced drug release, target accuracy, and bioavailability. Oncology, chronic disease management, and vaccine delivery are some of the applications explored in this paper to show how these materials improve the therapeutic results, counteract multidrug resistance, and allow for sustained and localized treatments. The review also discusses the translational barriers of bringing advanced materials into the clinical setting, which include issues of biocompatibility, scalability, and regulatory approval. Methods to overcome these challenges include surface modifications to reduce immunogenicity, scalable production methods such as microfluidics, and the harmonization of regulatory systems. In addition, the convergence of artificial intelligence (AI) and machine learning (ML) is opening new frontiers in material science and personalized medicine. These technologies allow for predictive modeling and real-time adjustments to optimize drug delivery to the needs of individual patients. The use of advanced materials can also be applied to rare and underserved diseases; thus, new strategies in gene therapy, orphan drugs development, and global vaccine distribution may offer new hopes for millions of patients.

Nanophotonic-enhanced photoacoustic imaging for brain tumor detection

Photoacoustic brain imaging (PABI) has emerged as a promising biomedical imaging modality, combining high contrast of optical imaging with deep tissue penetration of ultrasound imaging. This review explores the application of photoacoustic imaging in brain tumor imaging, highlighting the synergy between nanomaterials and state of the art optical techniques to achieve high-resolution imaging of deeper brain tissues. PABI leverages the photoacoustic effect, where absorbed light energy causes thermoelastic expansion, generating ultrasound waves that are detected and converted into images. This technique enables precise diagnosis, therapy monitoring, and enhanced clinical screening, specifically in the management of complex diseases such as breast cancer, lymphatic disorder, and neurological conditions. Despite integration of photoacoustic agents and ultrasound radiation, providing a comprehensive overview of current methodologies, major obstacles in brain tumor treatment, and future directions for improving diagnostic and therapeutic outcomes. The review underscores the significance of PABI as a robust research tool and medical method, with the potential to revolutionize brain disease diagnosis and treatment.

Phytochemicals and their Nanoformulations for Overcoming Drug Resistance in Head and Neck Squamous Cell Carcinoma

BACKGROUND

Drug resistance remains a significant challenge in the treatment of head and neck squamous cell carcinoma (HNSCC), leading to therapeutic failure and poor patient prognosis. Numerous mechanisms, including drug efflux pumps, altered tumor microenvironment (TME), and dysregulated cell death pathways, contribute to the development of resistance against conventional chemotherapeutic agents, immunotherapy, and targeted therapies. As resistance to traditional treatments continues to emerge, there is an urgent need for innovative therapeutic strategies to overcome these challenges. Phytochemicals are naturally occurring bioactive compounds and have demonstrated remarkable potential in targeting multiple resistance mechanisms simultaneously.

METHOD

This review comprehensively overviews the current understanding of drug resistance mechanisms in HNSCC and explores innovative strategies utilizing phytochemicals and their nanoformulations to overcome these resistance mechanisms, with a particular focus on recent developments and future perspectives in this field.

RESULTS AND DISCUSSION

Phytochemicals with anticancer properties include a wide range of herbal-derived molecules such as flavonoids, stilbenes, curcuminoids, alkaloids, traditional Chinese medicine, and others. These compounds can modulate ATP-binding cassette transporters, reverse epithelial-to-mesenchymal transition (EMT), target cancer stem cells (CSCs), and regulate various signaling pathways involved in drug resistance. The integration of phytochemicals into advanced nanoformulation systems has also shown a remarkable improvement in enhancing their bioavailability, stability, and targeted delivery to the TME, potentially improving their therapeutic efficacy. Furthermore, the combination of phytochemicals with conventional chemotherapeutic agents, targeted molecular therapy, and immune checkpoint inhibitors (ICIs) has exhibited synergistic effects, offering a promising approach to restoring drug sensitivity in resistant HNSCC cells.

CONCLUSION

Phytochemicals and their nanoformulations may improve response of HNSCC to therapy by alleviating drug resistance.

Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems

Melanoma, a highly aggressive form of skin cancer, poses a major therapeutic challenge due to its metastatic potential, resistance to conventional therapies, and the complexity of the tumor microenvironment (TME). Materials science and nanotechnology advances have led to using nanocarriers such as liposomes, dendrimers, polymeric nanoparticles, and metallic nanoparticles as transformative solutions for precision melanoma therapy. This review summarizes findings from Web of Science, PubMed, EMBASE, Scopus, and Google Scholar and highlights the role of nanotechnology in overcoming melanoma treatment barriers. Nanoparticles facilitate passive and active targeting through mechanisms such as the enhanced permeability and retention (EPR) effect and functionalization with tumor-specific ligands, thereby improving the accuracy of drug delivery and reducing systemic toxicity. Stimuli-responsive systems and multi-stage targeting further improve therapeutic precision and overcome challenges such as poor tumor penetration and drug resistance. Emerging therapeutic platforms combine diagnostic imaging with therapeutic delivery, paving the way for personalized medicine. However, there are still issues with scalability, biocompatibility, and regulatory compliance. This comprehensive review highlights the potential of integrating nanotechnology with advances in genetics and proteomics, scalable, and patient-specific therapies. These interdisciplinary innovations promise to redefine the treatment of melanoma and provide safer, more effective, and more accessible treatments. Continued research is essential to bridge the gap between evidence-based scientific advances and clinical applications.

Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development

Polymerase chain reaction (PCR) chips are advanced, microfluidic platforms that have revolutionized biomarker discovery and validation because of their high sensitivity, specificity, and throughput levels. These chips miniaturize traditional PCR processes for the speed and precision of nucleic acid biomarker detection relevant to advancing drug development. Biomarkers, which are useful in helping to explain disease mechanisms, patient stratification, and therapeutic monitoring, are hard to identify and validate due to the complexity of biological systems and the limitations of traditional techniques. The challenges to which PCR chips respond include high-throughput capabilities coupled with real-time quantitative analysis, enabling researchers to identify novel biomarkers with greater accuracy and reproducibility. More recent design improvements of PCR chips have further expanded their functionality to also include digital and multiplex PCR technologies. Digital PCR chips are ideal for quantifying rare biomarkers, which is essential in oncology and infectious disease research. In contrast, multiplex PCR chips enable simultaneous analysis of multiple targets, therefore simplifying biomarker validation. Furthermore, single-cell PCR chips have made it possible to detect biomarkers at unprecedented resolution, hence revealing heterogeneity within cell populations. PCR chips are transforming drug development, enabling target identification, patient stratification, and therapeutic efficacy assessment. They play a major role in the development of companion diagnostics and, therefore, pave the way for personalized medicine, ensuring that the right patient receives the right treatment. While this tremendously promising technology has exhibited many challenges regarding its scalability, integration with other omics technologies, and conformity with regulatory requirements, many still prevail. Future breakthroughs in chip manufacturing, the integration of artificial intelligence, and multi-omics applications will further expand PCR chip capabilities. PCR chips will not only be important for the acceleration of drug discovery and development but also in raising the bar in improving patient outcomes and, hence, global health care as these technologies continue to mature.

Bioengineering stimuli-responsive organic-inorganic nanoarchitetures based on carboxymethylcellulose-poly-l-lysine nanoplexes: Unlocking the potential for bioimaging and multimodal chemodynamic-magnetothermal therapy of brain cancer cells

Regrettably, glioblastoma multiforme (GBM) remains the deadliest form of brain cancer, where the early diagnosis plays a pivotal role in the patient's therapy and prognosis. Hence, we report for the first time the design, synthesis, and characterization of new hybrid organic-inorganic stimuli-responsive nanoplexes (NPX) for bioimaging and killing brain cancer cells (GBM, U-87). These nanoplexes were built through coupling two nanoconjugates, produced using a facile, sustainable, green aqueous colloidal process ("bottom-up"). One nanocomponent was based on cationic epsilon-poly-l-lysine polypeptide (εPL) conjugated with ZnS quantum dots (QDs) acting as chemical ligand and cell-penetrating peptide (CPP) for bioimaging of cancer cells (QD@εPL). The second nanocomponent was based on anionic carboxymethylcellulose (CMC) polysaccharide surrounding superparamagnetic magnetite "nanozymes" (MNZ) behaving as a capping macromolecular shell (MNZ@CMC) for killing cancer cells through chemodynamic therapy (CDT) and magnetohyperthermia (MHT). The results demonstrated the effective production of supramolecular aqueous colloidal nanoplexes (QD@εPL_MNZ@CMC, NPX) integrated into single nanoplatforms, mainly electrostatically stabilized by εPL/CMC biomolecules with anticancer activity against U-87 cells using 2D and 3D spheroid models. They displayed nanotheranostics (i.e., diagnosis and therapy) behavior credited to the photonic activity of QD@εPL with luminescent intracellular bioimaging, amalgamated with a dual-mode killing effect of GBM cancer cells through CDT by nanozyme-induced biocatalysis and as "nanoheaters" by magnetically-responsive hyperthermia therapy.

The Use of Plant Viral Nanoparticles in Cancer Biotherapy-A Review

Cancer is a major global health problem that poses significant challenges. Conventional cancer therapies often have severe side effects, necessitating the development of novel therapeutic approaches that are more effective and less toxic. The utilization of plant viral nanoparticles is one of the more promising strategies for cancer biotherapy. Plant viral nanoparticles exhibit advantageous properties, including safety, high stability, rapid production and scalability, biocompatibility and biodegradability, structural uniformity, inherent immunogenicity, ease of modification and high update efficacy as well as lower cost implications, making them attractive vehicles for health applications. Various studies have demonstrated the efficacy of plant viral nanoparticles in targeted therapeutic drug/molecule delivery, tumor imaging and immunotherapy, highlighting their potential as a versatile platform for cancer biotherapy. The drawbacks of plant viral nanoparticles include their perceived ability to induce a hypersensitive/allergic immune response, non-well-defined regulatory approval processes as well as the reluctance of pharmaceutical companies to adapt their manufacturing processes to facilitate plant-based expression. This review discusses applications of plant virus-derived nanoparticles in cancer therapeutics and prospects for translating these findings into clinical practice.

Revolutionizing Nanovaccines: A New Era of Immunization

Infectious diseases continue to pose a significant global health threat. To combat these challenges, innovative vaccine technologies are urgently needed. Nanoparticles (NPs) have unique properties and have emerged as a promising platform for developing next-generation vaccines. Nanoparticles are revolutionizing the field of vaccine development, offering a new era of immunization. They allow the creation of more effective, stable, and easily deliverable vaccines. Various types of NPs, including lipid, polymeric, metal, and virus-like particles, can be employed to encapsulate and deliver vaccine components, such as mRNA or protein antigens. These NPs protect antigens from degradation, target them to specific immune cells, and enhance antigen presentation, leading to robust and durable immune responses. Additionally, NPs can simultaneously deliver multiple vaccine components, including antigens, and adjuvants, in a single formulation, simplifying vaccine production and administration. Nanovaccines offer a promising approach to combat food- and water-borne bacterial diseases, surpassing traditional formulations. Further research is needed to address the global burden of these infections. This review highlights the potential of NPs to revolutionize vaccine platforms. We explore their mechanisms of action, current applications, and emerging trends. The review discusses the limitations of nanovaccines, innovative solutions and the potential role of artificial intelligence in developing more effective and accessible nanovaccines to combat infectious diseases.

Monte Carlo Simulations in Nanomedicine: Advancing Cancer Imaging and Therapy

Monte Carlo (MC) simulations have become important in advancing nanoparticle (NP)-based applications for cancer imaging and therapy. This review explores the critical role of MC simulations in modeling complex biological interactions, optimizing NP designs, and enhancing the precision of therapeutic and diagnostic strategies. Key findings highlight the ability of MC simulations to predict NP bio-distribution, radiation dosimetry, and treatment efficacy, providing a robust framework for addressing the stochastic nature of biological systems. Despite their contributions, MC simulations face challenges such as modeling biological complexity, computational demands, and the scarcity of reliable nanoscale data. However, emerging technologies, including hybrid modeling approaches, high-performance computing, and quantum simulation, are poised to overcome these limitations. Furthermore, novel advancements such as FLASH radiotherapy, multifunctional NPs, and patient-specific data integration are expanding the capabilities and clinical relevance of MC simulations. This topical review underscores the transformative potential of MC simulations in bridging fundamental research and clinical translation. By facilitating personalized nanomedicine and streamlining regulatory and clinical trial processes, MC simulations offer a pathway toward more effective, tailored, and accessible cancer treatments. The continued evolution of simulation techniques, driven by interdisciplinary collaboration and technological innovation, ensures that MC simulations will remain at the forefront of nanomedicine's progress.

Chitosan Micro/Nanocapsules in Action: Linking Design, Production, and Therapeutic Application

pH sensitivity of chitosan allows for precise phase transitions in acidic environments, controlling swelling and shrinking, making chitosan suitable for drug delivery systems. pH transitions are modulated by the presence of cross-linkers by the functionalization of the chitosan chain. This review relays a summary of chitosan functionalization and tailoring to optimize drug release. The potential to customize chitosan for different environments and therapeutic uses introduces opportunities for drug encapsulation and release. The focus on improving drug encapsulation and sustained release in specific tissues is an advanced interpretation, reflecting the evolving role of chitosan in achieving targeted and more efficient therapeutic outcomes. This review describes strategies to improve solubility and stability and ensure the controlled release of encapsulated drugs. The discussion on optimizing factors like cross-linking density, particle size, and pH for controlled drug release introduces a deeper understanding of how to achieve specific therapeutic effects. These strategies represent a refined approach to designing chitosan-based systems, pushing the boundaries of sustained release technologies and offering new avenues for precise drug delivery profiles.

Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges

Malignant growth is expected to surpass other significant causes of death as one of the top reasons for dismalness and mortality worldwide. According to a World Health Organization (WHO) study, this illness causes approximately between 9 and 10 million instances of deaths annually. Chemotherapy, radiation, and surgery are the three main methods of treating cancer. These methods seek to completely eradicate all cancer cells while having the fewest possible unintended impacts on healthy cell types. Owing to the lack of target selectivity, the majority of medications have substantial side effects. On the other hand, nanomaterials have transformed the identification, diagnosis, and management of cancer. Nanostructures with biomimetic properties have been grown as of late, fully intent on observing and treating the sickness. These nanostructures are expected to be consumed by growth in areas with profound disease. Furthermore, because of their extraordinary physicochemical properties, which incorporate nanoscale aspects, a more prominent surface region, explicit geometrical features, and the ability to embody different substances within or on their outside surfaces, nanostructures are remarkable nano-vehicles for conveying restorative specialists to their designated regions. This review discusses recent developments in nanostructured materials such as graphene, dendrimers, cell-penetrating peptide nanoparticles, nanoliposomes, lipid nanoparticles, magnetic nanoparticles, and nano-omics in the diagnosis and management of cancer.

Liposomes and Niosomes: New trends and applications in the delivery of bioactive agents for cancer therapy

Lipid-based nanocarriers have been in continuous development as strategies to enhance drug delivery efficiency. Liposomes are delivery systems primarily composed of phospholipids and cholesterol (or other suitable stabilizers) that have transformed the pharmaceutical field by improving drug targeting and release control. The success of this technology is strongly attributed to phospholipids, which are components of cell membranes, forming a biocompatible system. Nevertheless, drawbacks related to their production cost and stability under certain conditions led to the development of niosomes by replacing phospholipids with non-ionic surfactants. Both liposomes and niosomes have been widely studied and optimized for the delivery of bioactive agents targeting many diseases, including cancer. They can improve the efficacy of cancer therapy by reducing toxicity and off-target effects. Due to the complexity of this disease, many approaches should be considered, and the composition and physical properties of liposomes and niosomes influence the outcomes. In this review, we discuss the role of liposomes and niosomes in delivering bioactives for cancer therapy, emphasizing their specific characteristics, associated challenges, and the latest advancements aimed at enhancing their effectiveness.

Utilizing Plant Phytoconstituents in Metal Oxide Nanoparticle Synthesis for Cancer Therapies

BACKGROUND

The metal oxide nanoparticles possess unique properties such as biological compatibility, superior reactivity, and capacity to develop reactive oxygen species, due to this they have drawn significant interest in cancer treatment. The various MONPs such as Cerium oxide, Copper oxide, Iron oxide, Titanium dioxide, and Zinc oxide have been investigated for several types of cancers including brain, breast, cervical, colon, leukemia, liver, lung, melanoma, ovarian, and prostate cancers. However, traditional physiochemical synthetic methods for MONPs commonly include toxic materials, a major concern that raises questions regarding their biocompatibility and safety.

OBJECTIVE

This study aims to investigate the role of plant phytoconstituents in the development of MONPs via green synthesis and explore the therapeutic effectiveness of MONPs in treating several types of cancer. Primarily, it examines the potential of plant phytoconstituents (phenolic compounds, flavonoids, glycosides, alkaloids, etc.) in the development of MONPs as well as their improved ability to target numerous types of cancer.

METHODS

A systemic search was conducted on recent literature, focusing on developing green MONPs by utilizing plants' phytoconstituents (plant extracts). The study of plant phytochemicals (present in different parts of a plant such as leaves, flowers, stems, peels, and roots) and their role in the synthesis of green metal oxide nanoparticles as well as their anticancer activity against several types of cancers was analyzed. Also focusing on their anticancer mechanism that involves ROS production, generates oxidative stress, and apoptosis leads to cancer inhibition.

RESULTS

Phytochemicals-mediated metal oxide nanoparticle synthesis revealed many advantages such as improved biological compatibility and enhanced sensitivity towards cancer cells. Phytochemicals present in plant extracts act as natural capping, reducing, and stabilizing agents, enhancing nanoparticle synthesis which leads to synergistic anticancer activity. Additionally, the natural antioxidant and anticancer activity of various phytochemicals enhances the therapeutic potential of metal oxide nanoparticles, producing them more effective against ROS-generated apoptosis and showing negligible toxicity towards normal cells.

CONCLUSION

The utilization of plant phytochemicals in metal oxide nanoparticle production presents a safe, eco-friendly, sustainable, and effective approach to developing effective and safer cancer nanomedicines. Green synthesis not only increases anticancer activity but also decreases the biocompatibility problems associated with the physiochemical synthetic approach. Further research needs to concentrate on improving this synergy to create a targeted phytochemical-based metal oxide nanoparticle for cancer therapeutics.

Recent development of nanotechnology-based approaches for gynecologic cancer therapy

Gynecological cancer is a life-threatening malignancy among women. Traditional therapies, including chemotherapy, often face challenges in terms of chemotherapeutic drug solubility and resistance, specificity, tumor site targeting, and toxicity to healthy tissues, leading to shortened efficacy and unfavorable patient outcomes and survival rates in patients with gynecologic malignancies. Recently, nanotechnology-based therapeutic methods such as targeted drug delivery and phototherapies have emerged as an appropriate alternative to overcome issues associated with traditional therapeutic methods. Specifically, nanomaterials and nanomaterial-based methods enhance the delivery of therapeutic/targeting agents to tumor sites and cellular uptakes and improve the tumor-suppressing effect. This review aims to provide an overview and future perspective on the potential impact of nanotechnology-based therapeutic methods for effective therapies for gynecologic cancer.

Advances in Nanotheranostic Systems for Concurrent Cancer Imaging and Therapy: An Overview of the Last 5 Years

The rapid development of nanotechnology during the last two decades has created new opportunities to design and generate more advanced nanotheranostics with diversified capabilities for diagnosis, drug delivery, and treatment response monitoring in a single platform. To date, several approaches have been employed in order to develop nanotheranostics. The purpose of this review is to briefly discuss the key components of nanotheranostic systems, to present the conventional and upcoming imaging and therapeutic modalities that employ nanotheranostic systems, and to evaluate recent progress in the field of cancer nanotheranostic systems in the past five years (2020-2024). Special attention is focused on the design of cancer nanotheranostic systems, their composition, specificity, potential for multimodal imaging and therapy, and in vitro and in vivo characterization.

Co-Amorphization, Dissolution, and Stability of Quench-Cooled Drug-Drug Coamorphous Supersaturating Delivery Systems with RT-Unstable Amorphous Components

Background: Supersaturating drug delivery systems (SDDSs) have gained significant attention as a promising strategy to enhance the solubility and bioabsorption of Biopharmaceutics Classification System (BCS) II drugs. To overcome challenges associated with polymer-based amorphous SDDS (aSDDS), coamorphous (CAM) systems have emerged as a viable alternative. Among them, "drug-drug" CAM (ddCAM) systems show considerable potential for combination drug therapy. However, many drugs in their pure amorphous forms are unstable at room temperature (RT), complicating their formation and long-term stability profiles. Consequently, limited knowledge exists regarding the behavior of ddCAMs containing RT-unstable components formed via quench cooling. Methods: In this study, we used naproxen (NAP), a RT-unstable amorphous drug, in combination with felodipine (FEL) or nitrendipine (NTP), two RT-stable amorphous drugs, to create "FEL-NAP" and "NTP-NAP" ddCAM pairs via quench cooling. Our work used a series of methods to perform a detailed analysis on the co-amorphization, dissolution, solubility, and stability profiles of ddCAMs containing RT-unstable drugs, contributing to advancements in co-amorphization techniques for generating SDDS. Results: This study revealed that the co-amorphization and stability profiles of ddCAMs containing RT-unstable components produced via a quench-cooling method were closely related to drug-drug pairing types and ratios. Both quench-cooling and incorporation into coamorphous systems improved the dissolution, solubility, and physical stability of individual APIs. Conclusions: Our findings provide deeper insight into the co-amorphization, dissolution, and stability characteristics of specific drug-drug coamorphous systems FEL-NAP and NTP-NAP, offering valuable guidance for developing new ddCAM coamorphous formulations containing some RT-unstable drugs.

Metal-Phenolic Networks: A Promising Frontier in Cancer Theranostics

The burgeoning field of cancer theranostics has been significantly advanced by the development of Metal-Phenolic Networks (MPNs), a new class of supramolecular architectures that integrate the advantages of metals and polyphenols. This review focuses on MPNs and their promising applications in cancer theranostics. Through a systematic literature search spanning from 2010 to 2023 in databases including PubMed, Scopus, and Web of Science. The period of search was justified by the rapid evolution of nanomaterials in cancer therapy, with MPNs emerging as a significant player in biomedical applications within the specified timeframe. This review discusses the classification and structure of polyphenolic compounds, as well as their mechanisms of action in cancer treatment. The applications of MPNs in chemotherapy drug delivery, photothermal therapy, chemodynamic therapy, biomedical imaging, and synergistic therapy are especially detailed. The authors emphasize the significance of MPNs in cancer nanomedicine and look forward to their future development directions.

Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers

Intracranial aneurysms, characterized by abnormal dilations of cerebral arteries, pose significant health risks due to their potential to rupture, leading to subarachnoid hemorrhage with high mortality and morbidity rates. This paper aim is to explore the innovative application of nanoparticles in treating intracranial aneurysms, offering a promising avenue for enhancing current therapeutic strategies. We took into consideration the pathophysiology of cerebral aneurysms, focusing on the role of hemodynamic stress, endothelial dysfunction, and inflammation in their development and progression. By comparing cerebral aneurysms with other types, such as aortic aneurysms, we identify pathophysiological similarities and differences that could guide the adaptation of treatment approaches. The review highlights the potential of nanoparticles to improve drug delivery, targeting, and efficacy while minimizing side effects. We discuss various nanocarriers, including liposomes and polymeric nanoparticles, and their roles in overcoming biological barriers and enhancing therapeutic outcomes. Additionally, we discuss the potential of specific compounds, such as Edaravone and Tanshinone IIA, when used in conjunction with nanocarriers, to provide neuroprotective and anti-inflammatory benefits. By extrapolating insights from studies on aortic aneurysms, new research directions and therapeutic strategies for cerebral aneurysms are proposed. This interdisciplinary approach underscores the potential of nanoparticles to positively influence the management of intracranial aneurysms, paving the way for personalized treatment options that could significantly improve patient outcomes.

Nanomedicine for cancer patient-centered care

Cancer is a leading cause of morbidity and mortality worldwide, and an increase in incidence is estimated in the next future, due to population aging, which requires the development of highly tolerable and low-toxicity cancer treatment strategies. The use of nanotechnology to tailor treatments according to the genetic and immunophenotypic characteristics of a patient's tumor, and to allow its targeted release, can meet this need, improving the efficacy of treatment and minimizing side effects. Nanomedicine-based approach for the diagnosis and treatment of cancer is a rapidly evolving field. Several nanoformulations are currently in clinical trials, and some have been approved and marketed. However, their large-scale production and use are still hindered by an in-depth debate involving ethics, intellectual property, safety and health concerns, technical issues, and costs. Here, we survey the key approaches, with specific reference to organ-on chip technology, and cutting-edge tools, such as CRISPR/Cas9 genome editing, through which nanosystems can meet the needs for personalized diagnostics and therapy in cancer patients. An update is provided on the nanopharmaceuticals approved and marketed for cancer therapy and those currently undergoing clinical trials. Finally, we discuss the emerging avenues in the field and the challenges to be overcome for the transfer of nano-based precision oncology into clinical daily life.

Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment

Next-generation immunotherapies have revolutionized cancer treatment, offering hope for patients with hard-to-treat tumors. This review focuses on the clinical applications and advancements of key immune-based therapies, including immune checkpoint inhibitors, CAR-T cell therapy, and new cancer vaccines designed to harness the immune system to combat malignancies. A prime example is the success of pembrolizumab in the treatment of advanced melanoma, underscoring the transformative impact of these therapies. Combination treatments, integrating immunotherapy with chemotherapy, radiation, and targeted therapies, are demonstrating synergistic benefits and improving patient outcomes. This review also explores the evolving role of personalized immunotherapy, guided by biomarkers, genomic data, and the tumor environment, to better target individual tumors. Although significant progress has been made, challenges such as resistance, side effects, and high treatment costs persist. Technological innovations, including nanotechnology and artificial intelligence, are explored as future enablers of these therapies. The review evaluates key clinical trials, breakthroughs, and the emerging immune-modulating agents and advanced delivery systems that hold great promise for enhancing treatment efficacy, reducing toxicity, and expanding access to immunotherapy. In conclusion, this review highlights the ongoing advancements in immunotherapy that are reshaping cancer care, with future strategies poised to overcome current challenges and further extend therapeutic reach.

The wonders of X-PDT: an advance route to cancer theranostics

Global mortality data indicates cancer as the second-leading cause of death worldwide. Therefore, there's a pressing need to innovate effective treatments to address this significant medical and societal challenge. In recent years, X-ray-induced photodynamic therapy (X-PDT) has emerged as a promising advancement, revolutionizing traditional photodynamic therapy (PDT) for deeply entrenched malignancies by harnessing penetrating X-rays as external stimuli. Recent developments in X-ray photodynamic therapy have shown a trend toward minimizing radiation doses to remarkably low levels after the proof-of-concept demonstration. Early detection and real-time monitoring are crucial aspects of effective cancer treatment. Sophisticated X-ray imaging techniques have been enhanced by the introduction of X-ray luminescence nano-agents, alongside contrast nanomaterials based on X-ray attenuation. X-ray luminescence-based in vivo imaging offers excellent detection sensitivity and superior image quality in deep tissues at a reasonable cost, due to unhindered penetration and unimpeded auto-fluorescence of X-rays. This review emphasizes the significance of X-ray responsive theranostics, exploring their mechanism of action, feasibility, biocompatibility, and promising prospects in imaging-guided therapy for deep-seated tumors. Additionally, it discusses promising applications of X-PDT in treating breast cancer, liver cancer, lung cancer, skin cancer, and colorectal cancer.

Elaboration of Functionalized Iron Oxide Nanoparticles by Microwave-Assisted Co-Precipitation: A New One-Step Method in Water

Iron oxide nanoparticles are extensively utilized in various fields, particularly in biomedical applications. For such uses, nanoparticles must meet specific criteria, including precise size, morphology, physico-chemical properties, stability, and biocompatibility. Microwave-assisted co-precipitation offers an efficient method for producing water-soluble nanoparticles. Functionalization with citrate during synthesis is crucial for achieving a stable colloidal solution. This study aims to compare the effectiveness of conventional co-precipitation with microwave-assisted co-precipitation. The synthesized nanoparticles were characterized using TEM, DLS, FTIR, XRD, and magnetic measurements. The findings indicate that the in situ citrate functionalization during synthesis results in stable, non-aggregated nanoparticles.

Trivalent Disulfide Unit-Masked System Efficiently Delivers Large Oligonucleotide

Oligonucleotide drugs are shining in clinical therapeutics, but efficient and safe delivery systems severely limit their widespread use. A disulfide unit technology platform based on dynamic thiol exchange chemistry at the cell membrane has the potential for drug delivery. However, the alteration of the disulfide unit CSSC dihedral angle induced by different substituents directly affects the effectiveness of this technology and its stability. Previously, we constructed a trivalent low dihedral angle disulfide unit that can effectively promote the cellular uptake of small molecules. Here, we constructed a novel disulfide unit-masked oligonucleotide hybrid based on a low dihedral angle disulfide unit, motivated by prodrug design. Cellular imaging results showed that such a system exhibited superior cellular delivery efficiency than the commercial Lipo2000 without cytotoxicity. The thiol reagents significantly reduced its cellular uptake (57-74%), which proved to be endocytosis-independent. In addition, in vivo distribution experiments in mice showed that such systems can be rapidly distributed in liver tissues with a duration of action of more than 24 h, representing a potential means of silencing genes involved in the pathogenesis of liver-like diseases. In conclusion, this trivalent disulfide unit-masked system we constructed can effectively deliver large oligonucleotide drugs.

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years in the median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing the formation of new vasculature (antiangiogenic treatments) or destroying formed tumor vasculature (vascular disrupting agents) show promise. This study summarizes the existing knowledge regarding the processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses the activation of redundant proangiogenic pathways, heightened tumor cell invasion and metastasis, resistance induced by hypoxia, creation of vascular mimicry channels, and regulation of the tumor immune microenvironment. Subsequently, we explore potential strategies to overcome this resistance, such as combining antiangiogenic therapies with other treatment methods, personalizing treatments for each patient, focusing on new therapeutic targets, incorporating immunotherapy, and utilizing drug delivery systems based on nanoparticles. Additionally, we would like to discuss the limitations of existing methods and potential future directions to enhance the beneficial effects of antiangiogenic treatments for patients with GBM. Therefore, this review aims to enhance the research outcome for GBM and provide a more promising opportunity by thoroughly exploring the mechanisms of resistance and investigating novel therapeutic strategies.